

Serina Therapeutics Announces Dr. Randall Moreadith, President and CEO, Will Present Keynote Talks at Multiple Upcoming Conferences in Early 2019

Huntsville, AL, December 3rd 2018

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology platform for drug development based upon polyoxazoline (POZ™), announced today that Dr. Randall Moreadith will be keynote speaker at multiple conferences in the first quarter of 2019.

“I am delighted that the exceptional work we are doing at Serina Therapeutics continues to be highlighted at major conferences in the life sciences,” stated Dr. Moreadith.

The upcoming conferences and venues in early 2019 are listed below.

January 6th, 2019 **“Progress in Parkinson’s and Other Movement Disorders”** panel at the 2nd Annual Neuroscience Innovation Forum, 6th January 2019, Marine's Memorial Club, San Francisco, USA on the eve of JP Morgan, the largest conference in biotechnology partnering in the US. This is the first time Dr. Moreadith has been invited to this conference.

February 12-13th, 2019, **BIO CEO and Investor**, to be held at the Marriott Marquis in New York, NY. Many consider this to be one of the largest assemblies of investors and biotechnology companies in a single forum, with almost half of the attendees representing major venture capital and hedge fund managers who seek new investment opportunities.

March 31-April 4, 2019, 257th Annual American Chemical Society Meeting, Invited Speaker at the **“4th International Poly(2-oxazolines) and Polypeptoids Symposium”** in Orlando, FL. This is the third consecutive symposium where Dr. Moreadith has been invited to be a keynote speaker.

Serina Therapeutics Pipeline

Serina Therapeutics has a robust pipeline of poly(oxazoline) polymer conjugates. The most advanced product candidate is SER-214, a first-in-class drug candidate that delivers rotigotine continuously following a single weekly subcutaneous administration. The Phase Ia program in patients with Parkinson’s disease has completed enrollment, and Serina plans to advance SER-214 into Phase II development in 2019 for both Parkinson’s disease and restless leg syndrome. In addition to this product candidate for early Parkinson’s disease, Serina has recently advanced SER-240 – a polymer conjugate of apomorphine, the most potent dopamine agonist known – into pre-clinical studies in monkeys. SER-240 is on track to enter Phase I development in 2H-2019. SER-240 will be developed for advanced patients with Parkinson’s disease who have significant daily “off” periods not controlled with optimal oral therapy. SER-240 is designed to deliver apomorphine continuously over a one week period following a single SC injection, and early studies in the monkey show this occurs without skin inflammation. Inflammatory skin reactions, including abscess formation, can occur with the current formulations of apomorphine that are administered as a daily 12-16 hour infusion (example – APO-Go). These formulations lead to a high incidence of nodule formation.

In addition to a growing pipeline of proprietary programs focused on movement disorders, pain and epilepsy Serina is currently collaborating with leading pharmaceutical companies to further unlock the promise of the POZ™ platform and is actively seeking new partnerships.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that is developing novel polymer therapeutics based on its proprietary polyoxazoline (POZ™) technology. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled thirteen approved polyethylene glycol (PEG) products

for various pharmaceutical partners. POZ™ technology provides strong differential characteristics that may demonstrate improved safety, tolerability and clinical benefits versus PEG and other polymer-based technologies.

For more information on Serina Therapeutics, please visit www.serinatherapeutics.com.